Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Daunorubicin
Drug ID BADD_D00590
Description A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Indications and Usage For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Daunorubicin is indicated in combination with [cytarabine] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843]
Marketing Status approved
ATC Code L01DB02
DrugBank ID DB00694
KEGG ID D07776
MeSH ID D003630
PubChem ID 30323
TTD Drug ID D01XWG
NDC Product Code Not Available
UNII ZS7284E0ZP
Synonyms Daunorubicin | Daunomycin | Rubomycin | Dauno-Rubidomycine | Dauno Rubidomycine | Rubidomycin | Daunoblastin | Daunoblastine | NSC-82151 | NSC 82151 | NSC82151 | Cerubidine | Daunorubicin Hydrochloride | Hydrochloride, Daunorubicin
Chemical Information
Molecular Formula C27H29NO10
CAS Registry Number 20830-81-3
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agitation17.02.05.012; 19.06.02.001--
Alopecia23.02.02.001--
Amnesia17.03.02.001; 19.20.01.001--
Anaemia01.03.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Angina pectoris02.02.02.002; 24.04.04.002--
Anxiety19.06.02.002--
Arrhythmia02.03.02.001---
Arthralgia15.01.02.001--
Asthenia08.01.01.001---
Ataxia08.01.02.004; 17.02.02.001--
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.002---
Back pain15.03.04.005--
Blood uric acid increased13.02.04.001---
Body temperature increased13.15.01.001---
Bundle branch block02.03.01.009---
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002---
Cardiac tamponade02.06.01.001--
Cardiomyopathy02.04.01.001---
Cellulitis11.02.01.001; 23.11.02.004---
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.002---
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Chills08.01.09.001; 15.05.03.016--
Confusional state17.02.03.005; 19.13.01.001--
Conjunctivitis06.04.01.002; 11.01.06.012--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene